- Centene maintains its forecast for the full year 2024 adjusted EPS (earnings per share) above $6.80.
- The current market estimate for full-year adjusted EPS stands at $6.85.
- Centene reaffirms its 2024 adjusted EPS forecast.
- The company plans to shift 20 to 30 cents of adjusted diluted EPS from the third quarter (Q3) to the fourth quarter (Q4).
- Projected Q3 adjusted diluted EPS is expected to be between $1.31 and $1.41.
- The remainder of the full-year adjusted diluted EPS will be realized in Q4.
- Analyst recommendations for Centene include 11 buys, 10 holds, and 0 sells.
Centene Corp on Smartkarma
Analysts on Smartkarma, like Baptista Research, are closely monitoring Centene Corp, a key player in the healthcare sector. In their recent report titled “Centene Corporation: Medicaid Managed Care Expansion and Optimization! – Major Drivers,” Centene’s strong financial performance in the first quarter of the year is highlighted. The company exceeded expected earnings per share, prompting an optimistic revision of their full-year forecast. While showing operational efficiency, the report also acknowledges ongoing challenges, painting a nuanced picture of Centene’s current status.
In another insightful analysis by Baptista Research, titled “Centene Corporation: Leveraging Dual Eligibles in Medicare and Medicaid & Other Major Drivers,” Centene’s strategic maneuvers and positive developments in the first quarter of 2024 take the spotlight. With a higher-than-expected adjusted EPS and an upward revision in full-year guidance, Centene’s strong performance at the beginning of the year is attributed to operational improvements and strategic realignments. Analysts continue to track Centene Corp closely to provide investors with valuable insights regarding its future prospects in the healthcare market.
A look at Centene Corp Smart Scores
Factor | Score | Magnitude |
---|---|---|
Value | 4 | |
Dividend | 1 | |
Growth | 5 | |
Resilience | 4 | |
Momentum | 4 | |
OVERALL SMART SCORE | 3.6 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Centene Corp, a multi-line managed care organization specializing in Medicaid and related programs, holds a promising long-term outlook based on its Smartkarma Smart Scores. With strong scores in Value, Resilience, and Momentum, the company demonstrates robust fundamentals and a steady performance trajectory. Particularly noteworthy is its high Growth score, indicating a potential for significant expansion and development in the coming years. However, its low Dividend score suggests a lower focus on distributing profits to shareholders. Overall, Centene Corp appears well-positioned for sustained growth and resilience in the managed care industry.
Centene Corporation, known for its Medicaid health plans across multiple states, stands out for its comprehensive range of services, including behavioral health and treatment compliance. The company’s impressive Smart Scores highlight its solid foundation and growth potential, underscoring its strategic positioning in the market. With a keen focus on value, coupled with resilience and momentum, Centene Corp is poised to capitalize on emerging opportunities and navigate challenges effectively. Investors looking for a growth-oriented healthcare investment may find Centene Corp an appealing choice for the long term.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
π‘ Before itβs here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- β Unlimited Research Summaries
- β Personalised Alerts
- β Custom Watchlists
- β Company Analytics and News
- β Events & Webinars